The Syndrome of Inappropriate Antidiuretic Hormone Secretion and Other Hypoosmolar Disorders



The Syndrome of Inappropriate Antidiuretic Hormone Secretion and Other Hypoosmolar Disorders


Joseph G. Verbalis



The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is produced when plasma levels of arginine vasopressin (AVP), the only known antidiuretic hormone (ADH), are elevated at times when physiologic AVP secretion from the posterior pituitary would normally be suppressed. Because the only clinical abnormality known to result from increased secretion of AVP is a decrease in the osmotic pressure of body fluids, the hallmark of SIADH is hypoosmolality. This clinical finding led to the identification of the first well described cases of this disorder in 19571 and the subsequent clinical investigations that resulted in the delineation of the essential characteristics of the syndrome.2 It is therefore appropriate to begin this chapter with a brief summary of some general issues concerning hypoosmolality and hyponatremia before discussing details that are specific to SIADH and related disorders associated with dilutional hypoosmolality of body fluids. Although much has been learned over the last five decades about the pathophysiology of SIADH and hyponatremia, it remains surprising how rudimentary our understanding is of some of the most basic aspects of this disorder.3,4 One particularly striking example of this is the controversy concerning the most appropriate rate of correction of hyponatremic patients.5 Nonetheless, recent and ongoing clinical and basic studies have continued to shed new light on many heretofore incompletely understood aspects of hypoosmolar disorders. In addition, we have begun an exciting new era with regard to the therapy of these disorders using antagonists of AVP receptors.6 Although some of the specific information contained in this chapter will undoubtedly become outdated in the future, the basic concepts underlying the pathophysiology, diagnosis, and therapy of hypoosmolar disorders have withstood the tests of time and clinical utility, and likely will remain valid for some time to come.


HYPOOSMOLALITY AND HYPONATREMIA


Incidence

Hypoosmolality is one of the most common disorders of fluid and electrolyte balance encountered in hospitalized patients. The incidence and prevalence of hypoosmolar disorders depend on the nature of the patient population being studied as well as on the laboratory methods and diagnostic criteria used to ascertain hyponatremia. Most investigators have used the serum sodium concentration ([Na+]) to determine the clinical incidence of hypoosmolality. When hyponatremia is defined as a serum [Na+] of less than 135 mEq per L, incidences as high as 15% to 30% have been observed in studies of both acutely and chronically7,8 hospitalized patients. These high incidences in hospitalized patients are corroborated by frequency analysis of a large population of hospitalized patients, which demonstrated that serum [Na+] and chloride concentrations were approximately 5 mEq per L lower than those in a control group of healthy, nonhospitalized subjects.9 However, incidences decrease to the range of 1% to 4% when only patients with serum [Na+] less than 130 to 131 mEq per L are included,10,11,12 which may represent a more appropriate level to define the occurrence of clinically significant cases of this disorder. Even when one uses these more stringent criteria to define hypoosmolality, incidences from 7% to 53% have been reported in institutionalized geriatric patients.13,14 Perhaps most importantly, reports of all studies to date have noted a high proportion of iatrogenic or hospital-acquired hyponatremia, which has accounted for as much as 40% to 75% of all patients studied.12,15,16 Therefore, although hyponatremia and hypoosmolality are exceedingly common, most cases are relatively mild and become manifest during the course of hospitalization.

These considerations could be interpreted to indicate that hypoosmolality is of relatively little clinical significance, but this conclusion is unwarranted for several reasons. First, severe hypoosmolality (serum [Na+] levels <120 mEq per L), although relatively uncommon, is associated with substantial morbidity and mortality.17,18 Second, even relatively mild hypoosmolality can quickly progress to more dangerous levels during the course of therapeutic management of other disorders. Third, overly rapid correction of hyponatremia can itself cause severe neurologic morbidity and mortality.19 Finally, it has been observed that mortality
rates are much higher, from threefold11,20 to 60-fold,12 in patients with even asymptomatic degrees of hypoosmolality compared to normonatremic patients. Although earlier studies associated increased mortality with serum [Na+] levels less than 130 mEq per L, more recent studies indicate an increased risk of mortality even when serum [Na+] levels decrease below 137 mEq per L.15 Remarkably, hyponatremia has been found to represent an independent predictor of worsened outcomes in virtually every disease ever studied, from congestive heart failure to tuberculosis to liver failure.16 Although this is probably because hypoosmolality is more an indicator of the severity of many underlying illnesses than it is an independent contributing factor to mortality, this presumption may not be true of all cases. These considerations emphasize the importance of a careful evaluation of all hyponatremic patients, regardless of the clinical setting in which they present.


Osmolality, Tonicity, and Serum [Na+]

As discussed in Chapter 4, the osmolality of body fluid normally is maintained within narrow limits by osmotically regulated AVP secretion and thirst. Although basal plasma osmolality can vary appreciably among individuals, the range in the general population under conditions of normal hydration lies between 275 and 295 mOsm per kg H2O. Plasma osmolality can be determined directly by measuring the freezing point depression or the vapor pressure of plasma. Alternatively, it can be calculated indirectly from the concentrations of the three major solutes in plasma:

Posm (mOsm/kg H2O) = 2 × [Na+] (mEq/L) + glucose (mg/dL)/18 + blood urea nitrogen (mg/dL)/2.8

Both methods produce comparable results under most conditions. Although either of these methods produces valid measures of total osmolality, this is not always equivalent to the effective osmolality, which is commonly referred to as the tonicity of the plasma. Only cell membrane impermeable solutes such as Na+ and Cl that remain relatively compartmentalized within the extracellular fluid (ECF) space are “effective” solutes, because these solutes create osmotic gradients across cell membranes and thus generate osmotic movement of water from the intracellular fluid (ICF) compartment into the ECF compartment. By contrast, solutes that readily permeate cell membranes (e.g., urea, ethanol, and methanol) are not effective solutes, because they do not create osmotic gradients across cell membranes and thus do not generate water movement between body fluid compartments. Only the concentrations of effective solutes in plasma should be used to ascertain whether clinically significant hyperosmolality or hypoosmolality is present because these are the only solutes that directly affect body fluid distribution.21

Sodium and its accompanying anions represent the bulk of the major effective plasma solutes, so hyponatremia and hypoosmolality are usually synonymous. However, there are two important situations in which hyponatremia will not reflect true hypoosmolality. The first is pseudohyponatremia, which is produced by marked elevations of either lipids or proteins in plasma. In such cases the concentration of Na+ per liter of plasma water is unchanged, but the concentration of Na+ per liter of plasma is artifactually decreased because of the larger relative proportion of plasma volume that is occupied by the excess lipids or proteins.22,23 However, the increased protein or lipid will not appreciably increase the total number of solute particles in solution, so the directly measured plasma osmolality will not be significantly affected under these conditions. Measurement of serum [Na+] by ion-specific electrodes, which is now commonly employed by most clinical laboratories, is less influenced by high concentrations of lipids or proteins than is measurement of serum [Na+] by flame photometry,24 although recent reports have demonstrated that such errors can nonetheless still occur when using autoanalyzers that require a dilution of the plasma sample.25,26,27

The second situation in which hyponatremia does not reflect true plasma hypoosmolality occurs when high concentrations of effective solutes other than Na+ are present in the plasma. The initial hyperosmolality produced by the additional solute causes an osmotic shift of water from the ICF to the ECF, which in turn produces a dilutional decrease in the serum [Na+]. Once equilibrium between both fluid compartments is achieved, the total effective osmolality remains relatively unchanged. This situation most commonly occurs with hyperglycemia and represents a frequent cause of hyponatremia in hospitalized patients, accounting for up to 10% to 20% of all cases.12 Misdiagnosis of true hypoosmolality in such cases can be avoided by measuring plasma osmolality directly, or alternatively by correcting the measured serum [Na+] by 1.6 mEq per L for each 100 mg per dL increase in serum glucose concentration above normal levels.28 Recent studies have shown a more complex relation between hyperglycemia and serum [Na+], and have suggested that a more accurate correction factor may be closer to 2.4 mEq per L.29 When the plasma contains significant amounts of unmeasured solutes, such as osmotic diuretics, radiographic contrast agents, and some toxins (e.g., ethanol, methanol, and ethylene glycol), plasma osmolality cannot be calculated accurately. In these situations, osmolality must be ascertained by direct measurement, although even this method does not yield an accurate measure of the true effective osmolality if the unmeasured solutes are noneffective solutes that permeate cell membranes (e.g., ethanol).

Because of the previously noted considerations, it should be apparent that the determination of whether true hypoosmolality is present can sometimes be difficult. Nevertheless, a straightforward and relatively simple approach will suffice in most cases:

1. The effective plasma osmolality should be calculated from the measured serum [Na+] and glucose concentration (2 × [Na+] + glucose/18); alternatively, the
measured serum [Na+] can simply be corrected by 1.6 to 2.4 mEq per L for each 100 mg per dL increase in serum glucose concentration greater than normal levels (100 mg per dL).

2. If the calculated effective plasma osmolality is <275 mOsm per kg H2O, or if the corrected serum [Na+] is <135 mEq per L, then significant hypoosmolality exists, providing that large concentrations of unmeasured solutes or pseudohyponatremia secondary to hyperlipidemia or hyperproteinemia are not present.

3. To eliminate the latter possibilities, plasma osmolality should also be measured directly in all cases in which the hyponatremia cannot be accounted for by elevated serum glucose levels. Absence of a discrepancy between the calculated and measured total plasma osmolality (<10 mOsm per kg H2O) will confirm the absence of significant amounts of unmeasured solutes, such as osmotic diuretics, radiocontrast agents, or ethanol; if a significant discrepancy between these measures is found (called an “osmolal gap”30), appropriate tests must then be conducted to rule out pseudohyponatremia or to identify possible unmeasured plasma solutes.21,31,32 Whether significant hypoosmolality exists in the latter case will depend on the nature of the unmeasured solutes; although this determination will not always be possible, the clinician will at least be alerted to uncertainty about the diagnosis of true hypoosmolality.


Pathogenesis of Hypoosmolality

Because water moves freely between the ICF and ECF across most cell membranes, osmolality will always be equivalent in both of these fluid compartments since water distributes between them in response to osmotic gradients. Consequently, total body osmolality must always be the same as both ECF and ICF osmolality. The bulk of body solute is comprised of electrolytes, namely the exchangeable Na+ (Na+E) in the ECF and the exchangeable K+ (K+E) in the ICF along with their associated anions, so total body osmolality will largely be a function of these parameters33,34:

OSMECF = OSMICF = total body osmolality = (ECF solute + ICF solute) / body water = (2 × Na+E + 2 × K+E + nonelectrolyte solute) /body water

Although these calculations represent an oversimplification of complex factors that determine the relative distribution of intracellular and extracellular solutes (there is a revision of the original Edelman equation for predicting serum [Na+] based on exchangeable body Na+ and K+),35 they are sufficiently accurate for the purpose of predicting changes in serum [Na+]. By definition, the presence of plasma hypoosmolality indicates a relative excess of water to solute in the ECF. From the preceding equations, it should be apparent that this can be produced either by an excess of body water, resulting in a dilution of remaining body solute, or alternatively by a depletion of body solute, either Na+ or K+, relative to the remaining body water. Table 70.1 summarizes the potential causes of hyponatremia categorized according to whether the initiating event is dilution or depletion of body solute. It should be recognized that such a classification represents an obvious oversimplification, because most clinical hypoosmolar states involve significant
components of both solute depletion and water retention. Nonetheless, it is conceptually useful as a starting point for understanding the mechanisms underlying the pathogenesis of hypoosmolality and as a framework for discussions of therapy of hypoosmolar disorders.








TABLE 70.1 Pathogenesis of Hypoosmolar Disorders
















































































































Depletion (Primary Decreases in Total Body Solute and Secondary Water Retention)



Renal Solute Loss




Diuretic use




Solute diuresis (glucose, mannitol)




Salt wasting nephropathy




Mineralocorticoid deficiency or resistance



Nonrenal Solute Loss




Gastrointestinal (diarrhea, vomiting, pancreatitis, bowel obstruction)




Cutaneous (sweating, burns)




Blood loss


Dilution (Primary Increases in Total Body Water and Secondary Solute Depletion)



Impaired Renal Free Water Excretion




Increased Proximal Reabsorption





Hypothyroidism




Impaired Distal Dilution





Syndrome of inappropriate antidiuretic hormone secretion





Glucocorticoid deficiency




Combined Increased Proximal Reabsorption and Impaired Distal Dilution





Congestive heart failure





Cirrhosis





Nephrotic syndrome



Decreased Urinary Solute Excretion




Beer potomania




Very low protein diet



Excess Water Intake




Primary polydipsia




Dilute infant formula




Fresh water drowning



Solute Depletion

Depletion of body solute can result from any significant losses of ECF. Whether via renal or nonrenal routes, body fluid losses by themselves rarely cause hypoosmolality because excreted or secreted body fluids are usually isotonic or hypotonic relative to plasma and therefore tend to increase plasma osmolality. Consequently, when hypoosmolality accompanies ECF losses it is generally the result of replacement of body fluid losses by more hypotonic solutions, thereby diluting the remaining body solutes. This often occurs when patients drink water or other hypotonic fluids in response to ongoing solute and water losses, and also when hypotonic intravenous fluids are administered to hospitalized patients.36 When the solute losses are marked, these patients can show all of the obvious signs of volume depletion (e.g., addisonian crisis). However, such patients often have a more deceptive clinical presentation because their volume deficits may be partially replaced by subsequently ingested or infused fluids. Moreover, they may not manifest signs or symptoms of cellular dehydration because osmotic gradients will draw water into the relatively hypertonic ICF. Therefore, clinical evidence of hypovolemia strongly supports solute depletion as the cause of plasma hypoosmolality, but absence of clinically evident hypovolemia never completely eliminates this as a possibility. Although ECF solute losses are responsible for most cases of depletion-induced hypoosmolality, ICF solute loss can also cause hypoosmolality as a result of osmotic water shifts from the ICF into the ECF.33 This mechanism likely contributes to some cases of diuretic-induced hypoosmolality in which depletion of total body K+ often occurs.37,38


Water Retention

Despite the obvious importance of solute depletion in some patients, most cases of clinically significant hypoosmolality are caused by increases in total body water rather than by primary loss of extracellular solute. This can occur because of either impaired renal free water excretion or excessive free water intake. However, the former accounts for most hypoosmolar disorders because normal kidneys have sufficient diluting capacity to allow excretion of up to 20 to 30 L per day of free water (see Chapter 4). Intakes of this magnitude are occasionally seen in a subset of psychiatric patients39,40 but not in most patients, including patients with SIADH in whom fluid intakes average 2 to 3 L per day.41 Consequently, dilutional hypoosmolality usually is the result of an abnormality of renal free water excretion. The renal mechanisms responsible for impairments in free water excretion can be subgrouped according to whether the major impairment in free water excretion occurs in proximal or distal parts of the nephron, or both (see Table 70.1).

Any disorder that leads to a decrease in glomerular filtration rate (GFR) causes increased reabsorption of both Na+ and water in the proximal tubule. As a result, the ability to excrete free water is limited because of decreased delivery of tubular fluid to the distal nephron. Disorders causing solute depletion through nonrenal mechanisms (e.g., gastrointestinal fluid losses) also produce this effect. Disorders that cause a decreased GFR in the absence of significant ECF losses are, for the most part, edema-forming states associated with decreased effective arterial blood volume (EABV) and secondary hyperaldosteronism.42,43 Although these conditions are typified by increased proximal reabsorption of both Na+ and fluid, it is now clear that in most cases water retention also results from increased distal reabsorption caused by nonosmotic baroreceptor-mediated stimulated increases in plasma AVP levels,44,45 with the possible exception of hypothyroidism.

Distal nephron impairments in free water excretion are characterized by an inability to dilute tubular fluid maximally. These disorders are usually associated with abnormalities in the secretion of AVP from the posterior pituitary. However, just as depletion-induced hypoosmolar disorders usually include an important component of secondary impairments of free water excretion, so do most dilution-induced hypoosmolar disorders involve significant degrees of secondary solute depletion. This was recognized even before the first clinical description of SIADH from studies of the effects of posterior pituitary extracts on water retention, which demonstrated that renal salt wasting was predominantly a result of the ECF volume expansion produced by the retained water.46 Therefore, after sustained increases in total body water secondary to inappropriately elevated AVP levels, sufficient secondary solute losses, predominantly as Na+, occur and can result in further lowering of plasma osmolality. The actual contribution of Na+ losses to the hypoosmolality of SIADH is variable and depends in part on both the rate and volume of water retention.47 The major factor responsible for secondary Na+ losses appears to be renal hemodynamic effects, and specifically the phenomenon of pressure natriuresis and diuresis induced by the volume expansion.48 However, volume-stimulated hormones such as atrial natriuretic peptide (ANP) are also elevated in response to the water retention of patients with SIADH,49,50 and it seems likely that these factors also contribute to the secondary natriuresis, possibly via interactions with intrarenal hemodynamic effects.51 Regardless of the actual mechanisms involved, the solute losses that occur secondary to water retention can be best understood in the context of volume regulation of the ICF and ECF compartments in response to induced hypoosmolality, which is discussed in the next section.

Some dilutional disorders do not fit particularly well into either category. Chief among these is the hyponatremia that sometimes occurs in patients who ingest large volumes
of beer with little food intake for prolonged periods, called “beer potomania.”52,53 Although the volume of fluid ingested may not seem sufficiently excessive to overwhelm renal diluting mechanisms, in these cases free water excretion is limited by very low urinary solute excretion thereby causing water retention and dilutional hyponatremia. A reported case in which hyponatremia occurred in an ovolactovegetarian with a very low protein intake but no beer ingestion is consistent with this pathophysiologic mechanism.54 However, because most such patients have very low salt intakes as well, it is likely that relative depletion of body Na+ stores also is a contributing factor to the hypoosmolality in at least some cases.55


Adaptation to Hyponatremia: ICF and ECF Volume Regulation

Many studies have indicated that the combined effects of water retention plus urinary solute excretion cannot adequately explain the degree of plasma hypoosmolality observed in patients.2,56,57 This observation originally led to the theory of cellular inactivation of solute.2 Simply stated, this theory suggested that as ECF osmolality falls, water moves into cells along osmotic gradients, thereby causing the cells to swell. At some point during this volume expansion, the cells osmotically “inactivate” some of their intracellular solutes as a defense mechanism to prevent continued cell swelling with subsequent detrimental effects on cell function and survival. As a result of this decrease in intracellular osmolality, water then shifts back out of the ICF into the ECF, but at the expense of further worsening the dilution-induced hypoosmolality. Despite the appeal of this theory, its validity has never been demonstrated conclusively in either human or animal studies.

An appealing alternative theory has been suggested by studies of cell volume regulation, in which cell volume is maintained under hypoosmolar conditions by extrusion of potassium rather than by osmotic inactivation of cellular solute.58,59 Whole brain volume regulation via similar types of electrolyte losses was first described by Yannet in 1940,60 and has long been recognized as the mechanism by which the brain was able to adapt to hyponatremia and limit brain edema to sublethal levels.61,62,63 Following the recognition that low molecular weight organic compounds, called organic osmolytes, also constituted a significant osmotic component of a wide variety of cell types, studies demonstrated the accumulation of these compounds in response to hyperosmolality in both kidney64 and brain65 tissue. Multiple groups have now shown that the brain loses organic osmolytes in addition to electrolytes during the process of volume regulation to hypoosmolar conditions in experimental animals66,67,68,69 and human patients.70 These losses occur relatively quickly (within 24 to 48 hours in rats) and can account for as much as one third of the brain solute losses during hyponatremia.71 Such coordinate losses of both electrolytes and organic osmolytes from brain tissue enables very effective regulation of brain volume during chronic hyponatremia (Fig. 70.1).72 Consequently, it is now clear that cell volume regulation in vivo in brain tissue occurs predominantly through depletion, rather than intracellular osmotic inactivation, of a variety of intracellular solutes. Ongoing experimental studies are better defining the complex cellular and molecular mechanisms that underlie this profound adaptation to hypoosmolality.






FIGURE 70.1 Schematic diagram of brain volume adaptation to hyponatremia. Under normal conditions brain osmolality and extracellular fluid (ECF) osmolality are in equilibrium (top panel; for simplicity the predominant intracellular solutes are depicted as K+ and organic osmolytes, and the extracellular solute as Na+). Following the induction of ECF hypoosmolality, water moves into the brain in response to osmotic gradients producing brain edema (dotted line, middle panel, #1). However, in response to the induced swelling the brain rapidly loses both extracellular and intracellular solutes (middle panel, #2). As water losses accompany the losses of brain solute, the expanded brain volume then decreases back toward normal (middle panel, #3). If hypoosmolality is sustained, brain volume eventually normalizes completely and the brain becomes fully adapted to the ECF hyponatremia (bottom panel).

Most studies have focused on volume regulation in the brain during hyponatremia, but all cells volume regulate to varying degrees,58 and there is little question that this process occurs throughout the body as whole organisms adapt to hypoosmolar conditions. Unexplained components of hyponatremia that led to previous speculation about cellular inactivation of solute are now better explained by cellular losses of both electrolyte and organic solutes as cells throughout the
body undergo volume regulation during hypoosmolar conditions. However, volume regulatory processes are not limited to cells. Although most cases of hyponatremia clearly result from initial water retention induced by stimulated antidiuresis, it has always seemed likely that the resulting natriuresis served the purpose of regulating the volumes of the ECF and intravascular spaces. Many experimental and clinical observations are consistent with ECF volume regulation via secondary solute losses. First, dilutional decreases in concentrations of most blood constituents other than Na+ and Cl do not occur in patients with SIADH,73 suggesting that their plasma volume is not nearly as expanded as would be predicted simply by the measured decreases in serum [Na+]. Second, an increased incidence of hypertension has never been observed in patients with SIADH,74 again arguing against significant expansion of the arterial blood volume. Third, results of animal studies in both dogs75 and rats76 have clearly indicated that a significant component of chronic hyponatremia is attributable to secondary Na+ losses rather than water retention. Furthermore, the relative contributions from water retention versus sodium loss vary with the duration and severity of the hyponatremia: water retention was found to be the major cause of decreased serum [Na+] in the first 24 hours of induced hyponatremia in rats, but Na+ depletion then became the predominant etiologic factor after longer periods (7-14 days) of sustained hyponatremia, particularly at very low (<115 mEq per L) serum [Na+] levels.76 Finally, multiple studies have attempted to measure body fluid compartment volumes in hyponatremic patients, but without consistent results that indicate either plasma or ECF volume expansion.1,57,77,78 In particular, a report of body fluid space measurements using isotope dilution techniques in hyponatremic and normonatremic patients with small cell lung carcinoma showed no differences between the two groups with regard to exchangeable sodium space, ECF volume by 35SO4 distribution, or total body water.79 Such results have traditionally been explained by the relative insensitivity of isotope dilution techniques for measurement of body fluid compartment spaces, but an equally plausible possibility is that in the chronically adapted hyponatremic state body fluid compartments have regulated their volumes back toward normal via a combination of extracellular (predominantly electrolyte) and intracellular (electrolyte and organic osmolyte) solute losses.80 Figure 70.2 schematically illustrates some of the volume regulatory processes that likely occur in response to water retention induced by inappropriate antidiuresis. The degree to which solute losses versus water retention contribute to the resulting hyponatremia will vary in association with many different factors, including the etiology of the hyponatremia, the rapidity of development of the hyponatremia, the chronicity of the hyponatremia, the volume of daily water loading and subsequent volume expansion, and undoubtedly some degree of individual variability as well. It therefore hardly seems surprising that studies of hyponatremic patients have failed to yield uniform results regarding the pathogenesis of hyponatremia in view of the marked diversity of hyponatremic patients and their presentation at different times during the process of adaptation to hypoosmolality via volume regulatory processes.


Differential Diagnosis of Hyponatremia and Hypoosmolality

Because of the multiplicity of disorders causing hypoosmolality and the fact that many involve more than one pathologic mechanism, a definitive diagnosis is not always possible at the time of initial presentation. Nonetheless, a relatively straightforward approach based on the commonly used parameters of ECF volume status and urine sodium concentration generally allows a sufficient categorization of the underlying etiology to allow appropriate decisions regarding initial therapy and further evaluation in most cases (Table 70.2).


Decreased Extracellular Fluid Volume

The presence of clinically detectable hypovolemia nearly always signifies total body solute depletion. A low urine [Na+] indicates a nonrenal cause of solute depletion. If the urine [Na+] is high despite hypoosmolality, renal causes of solute depletion are likely responsible. Therapy with thiazide diuretics is the most common cause of renal solute losses,38 particularly in the elderly,81,82 but mineralocorticoid deficiency as a result of adrenal insufficiency83 or mineralocorticoid resistance84 must always be considered as well. Less commonly, renal solute losses may be the result of a salt-wasting nephropathy (e.g., polycystic kidney disease,85 interstitial nephritis,86 or chemotherapy87).


Increased Extracellular Fluid Volume

The presence of clinically detectable hypervolemia usually signifies total body Na+ excess. In these patients, hypoosmolality results from an even greater expansion of total body water caused by a marked reduction in the rate of water excretion (and sometimes an increased rate of water ingestion). The impairment in water excretion is secondary to a decreased EABV,42,43 which increases the reabsorption of glomerular filtrate not only in the proximal nephron but also in the distal and collecting tubules by stimulating AVP secretion.44,45 These patients generally have a low urine [Na+] because of secondary hyperaldosteronism, which is also a product of decreased EABV. However, under certain conditions urine [Na+] may be elevated, usually secondary to concurrent diuretic therapy but also sometimes because of a solute diuresis (e.g., glucosuria in diabetics) or after successful treatment of the underlying disease (e.g., ionotropic therapy in patients with congestive heart failure). An additional disorder that can produce hypoosmolality and hypervolemia is acute or chronic renal failure with fluid overload12 (although in early stages of renal failure polyuria from AVP resistance is more likely88). Urine [Na+] in these cases is usually elevated, but it can be variable depending on the stage of renal failure. It is important to remember that primary polydipsia will not be accompanied by signs of hypervolemia because water ingestion alone, in the absence of Na+ retention, does not typically produce clinically apparent degrees of ECF volume expansion.







FIGURE 70.2 Schematic illustration of potential changes in whole body fluid compartment volumes at various times during adaptation to hyponatremia. Under basal conditions the concentration of effective solutes in the extracellular fluid ([S]ECF) and the intracellular fluid ([S]ICF) are in osmotic balance (A). During the first phase of water retention resulting from inappropriate antidiuresis the excess water distributes across total body water, causing expansion of both ECF and ICF volumes (dotted lines) with equivalent dilutional decreases in [S]ICF and [S]ECF (B). In response to the volume expansion, compensatory volume regulatory decreases (VRD) occur to reduce the effective solute content of both the ICF (via increased electrolyte and osmolyte extrusion mediated by stretch activated channels and down-regulation of synthesis of osmolytes and osmolyte uptake transporters) and the ECF (via pressure diuresis and natriuretic factors) (C). If both processes go to completion, such as under conditions of fluid restriction, a final steady state can be reached in which ICF and ECF volumes have returned to normal levels but [S]ICF and [S]ECF remain low (E). In most cases this final steady state is not reached, and moderate degrees of ECF and ICF expansion persist, but significantly less than would be predicted from the decrease in body osmolality (D). Consequently, the degree to which hyponatremia is due to dilution from water retention versus solute depletion from volume regulatory processes can vary markedly depending on which phase of adaptation the patient is in, and also on the relative rates at which the different compensatory processes occur (e.g., delayed ICF VRD can worsen hyponatremia due to shifts of intracellular water into the extracellular fluid as intracellular organic osmolytes are extruded and subsequently metabolized, likely accounting for some component of the hyponatremia unexplained by the combination of water retention and sodium excretion in previous clinical studies). (From Verbalis JG. Hyponatremia: epidemiology, pathophysiology, and therapy. Curr Opin Nephrol Hyperten. 1993;2:636-652, with permission.)


Normal Extracellular Fluid Volume

Many different hypoosmolar disorders can potentially present clinically with euvolemia, in large part because it is difficult to detect modest changes in volume status using standard methods of clinical assessment; in such cases, measurement of urine [Na+] is an especially important first step.89 A high urine [Na+] in euvolemic patients usually implies a distally mediated, dilution-induced hypoosmolality such as SIADH. However, glucocorticoid deficiency can mimic SIADH so closely that these two disorders are often
indistinguishable in terms of water balance.90,91 Hyponatremia from diuretic use also can present without clinically evident hypovolemia, and the urine [Na+] will often be elevated in such cases because of the renal tubular effects of the diuretics.38 Recent studies have suggested that the fractional excretion of uric acid may provide a better measure of ECF volume status in hyponatremic patients on diuretics.92 A low urine [Na+] suggests a depletion-induced hypoosmolality from ECF losses with subsequent volume replacement by water or other hypotonic fluids. The solute loss often is generally nonrenal in origin, but an important exception is recent cessation of diuretic therapy, because urine [Na+] can quickly decrease to low values within 12 to 24 hours after discontinuation of the diuretic. The presence of a low serum [K+] is an important clue to diuretic use, because few of the other disorders that cause hypoosmolality are associated with significant hypokalemia. However, even in the absence of hypokalemia, any hypoosmolar, clinically euvolemic patient taking diuretics should be assumed to have solute depletion and treated accordingly; subsequent failure to correct the hypoosmolality with isotonic saline administration and persistence of an elevated urine [Na+] after discontinuation of diuretics then requires reconsideration of a diagnosis of dilutional hypoosmolality. A low urine [Na+] also can also be seen in some cases of hypothyroidism, in the early stages of decreased EABV before the development of clinically apparent sodium retention and fluid overload, or during the recovery phase from SIADH. Hence, a low urine [Na+] is less meaningful diagnostically than is a high value.








TABLE 70.2 Differential Diagnosis of Hyponatremia













































Extracellular Fluid Volume


Urine [Na+]a


Presumptive Diagnosis



Low


Depletion (Nonrenal): gastrointestinal, cutaneous, or blood ECF loss



High


Depletion (Renal): diuretics, mineralocorticoid insufficiency (Addison disease), salt losing nephropathy




Depletion (Nonrenal): any cause + hypotonic fluid replacement



Low


Dilution (Proximal): hypothyroidism, early decreased effective arterial blood volume




Dilution (Distal): SIADH, glucocorticoid insufficiency



High


Dilution( Distal): SIADH + fluid restriction




Depletion (Renal): any cause + hypotonic fluid replacement (especially diuretic treatment)



Low


Dilution (Proximal): decreased, effective arterial blood volume (congestive heart failure, cirrhosis, nephrosis)



High


Dilution (Proximal): any cause + diuretics or improvement in underlying disease, renal failure


a Urine [Na+] values <30 mEq per L are generally considered to be low and values ≥30 mEq per day to be high, based on studies of responses of hyponatremic patients to infusions of isotonic saline.89


Because euvolemic causes of hypoosmolality represent the most challenging etiologies of this disease, both in terms of differential diagnosis as well as with regard to the underlying pathophysiology, the subsequent sections will discuss the major causes of euvolemic hypoosmolality and hyponatremia in greater detail.


SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION

SIADH is the most common cause of euvolemic hypoosmolality. It is also the single most prevalent cause of hypoosmolality of all etiologies encountered in clinical practice, with prevalence rates ranging from 20% to 40% among all hypoosmolar patients.12,41,93,94 The clinical criteria necessary to diagnose SIADH remain basically as set forth by Bartter and Schwartz in 1967.2 A modified summary of these criteria is presented in Table 70.3 along with several other clinical
findings that support this diagnosis. Several points about each of these criteria deserve emphasis and/or qualification:








TABLE 70.3 Criteria for the Diagnosis of SIADH























Essential


Decreased effective osmolality of the extracellular fluid (Posm <275 mOsm/kg H2O)


Inappropriate urinary concentration (Uosm >100 mOsm/kg H2O with normal renal function) at some level of hypoosmolality


Clinical euvolemia, as defined by the absence of signs of hypovolemia (orthostasis, tachycardia, decreased skin turgor, dry mucous membranes) or hypervolemia (subcutaneous edema, ascites)


Elevated urinary sodium excretion while on a normal salt and water intake


Absence of other potential causes of euvolemic hypoosmolality: hypothyroidism, hypocortisolism (Addison disease or pituitary ACTH insufficiency), and diuretic use


Supplemental


Abnormal water load test (inability to excrete at least 90% of a 20 mL/kg water load in 4 hours and/or failure to dilute Uosm to <100 mOsm/kg H2O)


Plasma AVP level inappropriately elevated relative to plasma osmolality


No significant correction of serum [Na+] with volume expansion but improvement after fluid restriction


1. True hypoosmolality must be present and hyponatremia secondary to pseudohyponatremia or hyperglycemia alone must be excluded.

2. Urinary concentration (osmolality) must be inappropriate for plasma hypoosmolality. This does not mean that urine osmolality must be greater than plasma osmolality (a common misinterpretation of this criterion), but simply that the urine must be less than maximally dilute (i.e., urine osmolality >100 mOsm per kg H2O). It also should be remembered that urine osmolality need not be elevated inappropriately at all levels of plasma osmolality, because in the reset osmostat variant of SIADH, AVP secretion can be suppressed with resultant maximal urinary dilution and free water excretion if plasma osmolality is decreased to sufficiently low levels.95,96 Hence, to satisfy the classical criteria for the diagnosis of SIADH, it is necessary only that urine osmolality be inadequately suppressed at some level of plasma osmolality less than 275 mOsm per kg H2O.

3. Clinical euvolemia must be present to establish a diagnosis of SIADH, because both hypovolemia and hypervolemia strongly suggest different causes of hypoosmolality. This does not mean that patients with SIADH cannot become hypovolemic or hypervolemic for other reasons, but in such cases it is impossible to diagnose the underlying inappropriate antidiuresis until the patient is rendered euvolemic and found to have persistent hypoosmolality.

4. The criterion of renal “salt-wasting” has probably caused the most confusion regarding diagnosis of SIADH. This criterion is included because of its utility in differentiating between hypoosmolality caused by a decreased EABV, in which case renal Na+ conservation occurs, and distal dilution-induced disorders, in which urinary Na+ excretion is normal or increased secondary to ECF volume expansion. However, two important qualifications limit the utility of urine [Na+] measurement in the hypoosmolar patient: urine [Na+] also is high when solute depletion is of renal origin, as seen with diuretic use or Addison disease, and patients with SIADH can have low urine Na+ excretion if they subsequently become hypovolemic or solute depleted, conditions that sometimes follow severe sodium and water restriction. Consequently, although a high urine Na+ excretion is the rule in most patients with SIADH, its presence does not guarantee this diagnosis, and, conversely, its absence does not rule out the diagnosis.

5. The final criterion emphasizes that SIADH remains a diagnosis of exclusion. Thus, the presence of other potential causes of euvolemic hypoosmolality must always be excluded. This includes not only thyroid and adrenal dysfunction, but also diuretic use, because this can also sometimes present as euvolemic hypoosmolality.

Table 70.3 also lists several other criteria that support, but are not essential for a diagnosis of SIADH. The first of these, the water load test, is of value when there is uncertainty regarding the etiology of modest degrees of hypoosmolality in euvolemic patients, but it does not add useful information if the plasma osmolality is <275 mOsm per kg H2O. Inability to excrete a standard water load normally (with normal excretion defined as a cumulative urine output of at least 90% of the administered water load within 4 hours, and suppression of urine osmolality to <100 mOsm per kg H2O97) confirms the presence of an underlying defect in free water excretion. Unfortunately, water loading is abnormal in almost all disorders that cause hypoosmolality, whether dilutional or depletion-induced with secondary impairments in free water excretion. Two exceptions are primary polydipsia, in which hypoosmolality can rarely be secondary to excessive water intake alone, and the reset osmostat variant of SIADH, in which normal excretion of a water load can occur once plasma osmolality falls below the new set point for AVP secretion. The water load test may also be used
to assess water excretion after treatment of an underlying disorder thought to be causing SIADH. For example, after discontinuation of a drug associated with SIADH in a patient who has already achieved a normal plasma osmolality by fluid restriction, a normal water load test can confirm the absence of persistent inappropriate antidiuresis much more quickly than can simple monitoring of the serum [Na+] during a period of ad libitum fluid intake. Despite these limitations as a diagnostic clinical test, the water load test remains an extremely useful tool in clinical research for quantitating changes in free water excretion in response to physiologic or pharmacologic manipulations.

The second supportive criterion for a diagnosis of SIADH is an inappropriately elevated plasma AVP level in relation to plasma osmolality. At the time that SIADH was originally described, inappropriately elevated plasma levels of AVP were merely postulated because the measurement of plasma levels of AVP was limited to relatively insensitive bioassays. With the development of sensitive AVP radioimmunoassays capable of detecting the small physiologic concentrations of this peptide that circulate in plasma,98 there was hope that measurement of plasma AVP levels might supplant the classic criteria and become the definitive test for diagnosing SIADH, as is the case for many syndromes of hormone hypersecretion. This has not occurred for several reasons. First, although plasma AVP levels are elevated in most patients with this syndrome, the elevations generally remain within the normal physiologic range and are abnormal only in relation to plasma osmolality (Fig. 70.3). Therefore, AVP levels can be interpreted only in conjunction with a simultaneous plasma osmolality and knowledge of the relation between AVP levels and plasma osmolality in normal subjects (see Chapter 4). Second, 10% to 20% of patients with SIADH do not have measurably elevated plasma AVP levels; as shown in Figure 70.3, many such patients have AVP levels that are at, or even below, the limits of detection by radioimmunoassay. Whether these cases are true examples of inappropriate antidiuresis in the absence of circulating AVP, or whether they simply represent inappropriate AVP levels that fall below the limits of detection by radioimmunoassay, is not clear. For this reason, Zerbe et al. have proposed using the term SIAD (syndrome of inappropriate antidiuresis) rather than SIADH to describe this entire group of disorders.99 Studies of hyponatremic children have discovered two genetic mutations of the vasopressin V2 receptor (V2R) that were responsible for constitutive activation of antidiuresis in the absence of AVP-V2R ligand binding.100 The true incidence of these, and similar V2R mutations, as well as how often they are responsible for patients with SIADH but low or unmeasurable plasma AVP levels, remains to be determined. Third, just as water loading fails to distinguish among various causes of hypoosmolality, so do plasma AVP levels. Many disorders causing solute and volume depletion are associated with elevations of plasma AVP levels secondary to hemodynamic stimuli. For similar reasons, patients with disorders that cause decreased EABV, such as congestive heart failure and cirrhosis, also have elevated AVP levels (see Chapters 67 and 68). Even glucocorticoid insufficiency has been associated with inappropriately elevated AVP levels, as is discussed in the following section.101 Therefore, multiple different disorders cause stimulation of AVP secretion via nonosmotic mechanisms, rendering this measurement of relatively limited differential diagnostic value. Recent studies using a newly developed assay for copeptin, the glycopeptide C-terminal fragment of the AVP prohormone, have confirmed AVP secretion in most cases of dilutional hyponatremia except for primary polydipsia, where this measurement may prove to be of use diagnostically.102

Finally, an improvement in plasma osmolality with fluid restriction but not with volume expansion can sometimes be helpful in differentiating between disorders causing solute depletion and those associated with dilution-induced hypoosmolality. Infusion of isotonic NaCl in patients with SIADH provokes a natriuresis with little correction of osmolality, whereas fluid restriction allows such patients to achieve solute and water balance gradually through insensible free water losses.1 In contrast, isotonic saline is the treatment of choice in disorders of solute depletion, because once volume deficits are corrected the stimulus to continued AVP secretion and free water retention is eliminated. The diagnostic value of this therapeutic response is limited somewhat by the fact that patients with proximal types of dilution-induced disorders may show a response similar to that found in patients with SIADH. However, the major drawback is that this represents a retrospective test in a situation in which
it would be preferable to establish a diagnosis before making a decision regarding treatment options. Nonetheless, in difficult cases of euvolemic hypoosmolality, an appropriate therapeutic response can sometimes be helpful in confirming a diagnosis of SIADH.






FIGURE 70.3 Plasma AVP levels in patients with SIADH as a function of plasma osmolality. Each point depicts one patient at a single point in time. The shaded area represents AVP levels in normal subjects over physiologic ranges of plasma osmolality. The lowest measurable plasma AVP levels using this radioimmunoassay was 0.5 pg per mL. (From Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med. 1982;72:339-353, with permission.)


Etiology

Although the list of disorders associated with SIADH is long, they can be divided into four major etiologic groups (Table 70.4).


Tumors

One of the most common associations of SIADH remains with tumors. Although many different types of tumors have been associated with SIADH (Table 70.4), bronchogenic carcinoma of the lung has been uniquely associated with SIADH since the first description of this disorder in 1957.1 In virtually all cases, the bronchogenic carcinomas causing this syndrome have been of the small cell variety; a few squamous cell types have been described, but these are rare. Incidences of hyponatremia as high as 11% of all patients with smallcell carcinoma,103 or 33% of cases with more extensive disease,104 have been reported. The unusually high incidence of small cell carcinoma of the lung in patients with SIADH, together with the relatively favorable therapeutic response of this type of tumor, makes it imperative that all patients presenting with an otherwise unexplained SIADH be investigated thoroughly and aggressively for a possible tumor. The evaluation should include a computed tomography (CT) or magnetic resonance imaging (MRI) scan of the thorax. In cases with a high degree of suspicion (e.g., hyponatremia in a young smoker) bronchoscopy with cytologic analysis of bronchial washings should be considered even if the results of routine chest radiography are normal, since several studies have reported hypoosmolality that predated any radiographically evident abnormality in patients who then were found to harbor bronchogenic carcinomas 3 to 12 months later.105,106 Head and neck cancers account for another group of malignancies associated with relatively higher incidences of SIADH,107 and some of these tumors have clearly been shown to be capable of synthesizing AVP ectopically.108 A report from a large cancer hospital showed an incidence of hyponatremia for all malignancies combined of 3.7%, with approximately one third of these due to SIADH.20


Central Nervous System Disorders

The second major etiologic group of disorders causing SIADH has its origins in the central nervous system (CNS). Despite the large number of different CNS disorders associated with SIADH, there is no obvious common denominator linking them. However, this is actually not surprising when one considers the neuroanatomy of neurohypophysial innervation. The magnocellular AVP neurons receive excitatory inputs from osmoreceptor cells located in the anterior hypothalamus, but also have a major innervation from brainstem cardiovascular
regulatory and emetic centers (Fig. 70.4). Although various components of these pathways have yet to be fully elucidated, many of them appear to have inhibitory as well as excitatory components.109 Consequently, any diffuse CNS disorder can potentially cause AVP hypersecretion either by nonspecifically exciting these pathways via irritative foci, or alternatively by disrupting them and thereby decreasing the level of inhibition impinging upon the AVP neurons in the neurohypophysis. The wide variety of diverse CNS processes that can potentially cause SIADH stands in contrast to CNS causes of diabetes insipidus, which are for the most part limited to lesions localized to the hypothalamus and/or posterior pituitary that destroy the magnocellular vasopressin neurons (see Chapter 71).








TABLE 70.4 Common Etiologies of SIADH













































Tumors


Pulmonary/mediastinal (bronchogenic carcinoma; mesothelioma; thymoma)


Non-chest (duodenal carcinoma; pancreatic carcinoma; ureteral/prostate carcinoma; uterine carcinoma; nasopharyngeal carcinoma; leukemia)


Central Nervous System Disorders


Mass lesions (tumors; brain abscesses; subdural hematoma)


Inflammatory diseases (encephalitis; meningitis; systemic lupus; acute intermittent porphyria, multiple sclerosis)


Degenerative/demyelinative diseases (Guillain-Barré; spinal cord lesions)


Miscellaneous (subarachnoid hemorrhage; head trauma; acute psychosis; delirium tremens; pituitary stalk section; transsphenoidal adenomectomy; hydrocephalus)


Drug Induced


Stimulated AVP release (nicotine; phenothiazines; tricyclics)


Direct renal effects and/or potentiation of AVP antidiuretic effects (dDAVP; oxytocin; prostaglandin synthesis inhibitors)


Mixed or uncertain actions (amiodarone; angiotensin converting enzyme inhibitors; carbamazepine and oxcarbazepine; chlorpropamide; clofibrate; clozapine; cyclophosphamide; 3,4-methylenedioxymethamphetamine [ecstasy]; omeprazole; serotonin reuptake inhibitors; vincristine)


Pulmonary Diseases


Infections (tuberculosis; acute bacterial and viral pneumonia; aspergillosis; empyema)


Mechanical/ventilatory (acute respiratory failure; COPD; positive pressure ventilation)


Other


Acquired immunodeficiency syndrome and AIDS-related complex


Prolonged strenuous exercise (marathon; triathlon; ultramarathon; hot-weather hiking)


Chronic inflammation (IL-6)


Senile atrophy


Idiopathic







FIGURE 70.4 Diagrammatic summary of the primary brain pathways mediating AVP secretion in response to the major factors that stimulate pituitary AVP secretion. Osmolality activates neurons throughout the anterior hypothalamus, including the SFO and MnPO, but the OVLT appears to be uniquely sensitive to osmotic stimulation and is essential for osmotically stimulated AVP and OT secretion; in addition, osmotic stimulation can act directly on magnocellular neurons which themselves are intrinsically osmosensitive. Similarly, circulating angiotensin II activates cells throughout the OVLT and MnPO, but the SFO appears to be its major and essential site of action. For both of these stimuli, projections from the SFO and OVLT to the MnPO activate both excitatory and inhibitory interneurons that project to the SON and PVN and modulate the direct circumventricular inputs to these areas. Emetic stimuli act both on gastric vagal afferents which terminate in the NST and in some cases also act directly at the AP. Most of the AVP secretion appears to be a result of monosynaptic projections from catecholaminergic A2/C2 cells in the NST. Baroreceptor-mediated stimuli such as hypovolemia and hypotension are considerably more complex. Although they also arise from cranial nerves (IX and X) which terminate in the NST, most experimental data suggest that the major projection to magnocellular AVP neurons arises from catecholaminergic A1 cells of the VLM that are activated by excitatory interneurons from the NST, although some component might also arise from multisynaptic projections through other areas such as the PBN.AC, anterior commissure; AP, area postrema; AVP, arginine vasopressin; MnPO, median preoptic nucleus; NST, nucleus of the solitary tract; OC, optic chiasm; OT, oxytocin; OVLT, organum vasculosum of the lamina terminalis; PBN, parabrachial nucleus; PIT, anterior pituitary; PVN, paraventricular nucleus; SFO, subfornical organ; SON, supraoptic nucleus; VLM, ventrolateral medulla.



Pulmonary Disorders

Pulmonary disorders represent a relatively common but frequently misunderstood cause of SIADH. A variety of pulmonary disorders have been associated with this syndrome, but other than tuberculosis,128 acute pneumonia,129,130,131 and advanced chronic obstructive lung disease,132 the occurrence of hypoosmolality has been noted mainly in sporadic case reports. Some bacterial infections appear to be associated with a higher incidence of hyponatremia, particularly Legionella pneumoniae.133 Although one case of pulmonary tuberculosis has been reported that suggested the possibility that tuberculous lung tissue might synthesize AVP ectopically,134 several other studies have reported that advanced pulmonary tuberculosis is associated with the reset osmostat form of SIADH,96,128 presumably from nonosmotic stimulation of posterior pituitary AVP secretion. Most cases of pulmonary SIADH not associated with either tuberculosis or pneumonitis have occurred in the setting of respiratory failure. Although hypoxia has clearly been shown to stimulate AVP secretion in animals,135,136 it appears to be less effective as a stimulus in humans,137 in whom the stimulus to abnormal water retention appears to be hypercarbia more so than hypoxia.138,139 When such patients were evaluated serially, the inappropriate AVP secretion was found to be limited to the initial days of hospitalization, when respiratory failure was most marked.140 Even cases of tubercular SIADH generally have occurred in patients with far advanced, active, pulmonary tuberculosis, although interestingly hyponatremia was also found in 74% of a series of patients with miliary tuberculosis.141 Therefore, SIADH in non-tumor-related pulmonary disease generally conforms to the following characteristics: (1) the pulmonary disease will always be obvious as a result of severe dyspnea or extensive radiographically evident infiltrates, and (2) the inappropriate antidiuresis will usually be limited to the period of respiratory failure— once clinical improvement has begun, free water excretion generally improves rapidly. Mechanical ventilation can cause inappropriate AVP secretion, or it can worsen any SIADH caused by other factors. This phenomenon has been associated most often with continuous positive pressure ventilation,142 but it can also occur to a lesser degree with the use of positive end expiratory pressure.


Other Causes

One of the most recently described causes of hypoosmolality is the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC), in patients with human immunodeficiency virus (HIV) infection, with incidences of hyponatremia reported as high as 30% to 38% in adults143,144,145 and children.146 Although there are many potential etiologies for hyponatremia in patients with AIDS/ARC, including dehydration, adrenal insufficiency, and pneumonitis, from 12% to 68% of AIDS patients who develop hyponatremia appear to meet criteria for a diagnosis of SIADH.143,144,145 Not unexpectedly, reports have implicated some of the medications used to treat these patients as the cause of the hyponatremia, either via direct renal tubular toxicity or SIADH.147,148

A recent series of reports have documented a surprisingly high incidence of hyponatremia during endurance exercise events such as marathon149 and ultramarathon150 foot races, triathlons,151 forced marching,152 and hiking.153 Occasionally, this has caused fatal outcomes associated with hyponatremic encephalopathy from acute brain edema.154,155 Most studies support excess drinking during the exercise as the major cause of the induced hyponatremia,156,157 but it now appears that water retention under such conditions is also contributed to by SIADH as a result of multiple potential nonosmotic stimuli (e.g., volume depletion, nausea, increased cytokine levels).158,159

Unexplained or idiopathic causes account for a relatively small proportion of all cases of SIADH. Although the etiology of the syndrome may not be diagnosed initially in many cases, the numbers of patients in whom an apparent cause cannot be established after consistent follow-up over time are relatively few. However, an exception to this appears to be elderly patients who sometimes develop SIADH without any apparent underlying etiology.160,161,162 Coupled with the significantly increased incidence of hyponatremia in geriatric patients,7,13,14,93,163,164 this suggests that the normal aging process may be accompanied by abnormalities of regulation of AVP secretion that predispose to SIADH. Such an effect could potentially account for the fact that virtually all causes of drug-induced hyponatremia occur much more frequently in elderly patients.82,165,166 In several series of elderly patients meeting criteria for SIADH, 40% to 60% remained idiopathic despite rigorous evaluation,167,168,169 leading some to conclude that extensive diagnostic procedures were not warranted in such elderly patients if routine history, physical examination, and laboratory evaluation failed to suggest a diagnosis.167

Some well-known stimuli of AVP secretion are notable primarily because of their exclusion from Table 70.4. Despite unequivocal stimulation of AVP secretion by nicotine,170 cigarette smoking has only rarely been associated with SIADH,
and primarily in psychiatric patients who have several other potential causes of inappropriate AVP secretion.39,171,172 This is in part because of chronic adaptation to the effects of nicotine, but also because the short half-life of AVP in plasma (approximately 15 min in humans173) limits the duration of antidiuresis produced by relatively short-lived stimuli such as smoking. Although nausea remains the most potent stimulus to AVP secretion known in man,174 chronic nausea is rarely associated with hypoosmolality unless accompanied by vomiting with subsequent ECF solute depletion followed by ingestion of hypotonic fluids.175 Similar to smoking, this is probably attributable to the short half-life of AVP, but also to the fact that most such patients are not inclined to drink fluids under such circumstances. However, hyponatremia can occur when such patients are infused with high volumes of hypotonic fluids. This is likely a factor contributing to the hyponatremia that often occurs in cancer patients who are receiving chemotherapy.103 Finally, a causal relation between stress and SIADH has often been suggested, but never conclusively established. This underscores the fact that stress, independent of associated nausea, dehydration, or hypotension, is not a major stimulus causing sustained elevations of AVP levels in humans.176

May 29, 2016 | Posted by in NEPHROLOGY | Comments Off on The Syndrome of Inappropriate Antidiuretic Hormone Secretion and Other Hypoosmolar Disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access